EL7.AI
StocksMediumUpdated•Originally published 8 September 2026•Updated 8 September 2026•
1 min read

PDS Biotech Shares Surge Premarket Following $22.55M Financing Deal

Key Facts

1PDS Biotechnology announced it has raised up to $22.55 million in equity funding through a Private Investment in Public Equity (PIPE) transaction.
2The financing is led by Dr. Patrick Soon-Shiong, founder of NantWorks, who will also join the PDS Biotech Board of Directors.
3The company plans to use the funds to progress the development of PDS0301 immunocytokine in solid tumors.

In a move reflecting strategic investor confidence in the immunotherapy sector, PDS Biotechnology announced it has raised up to $22.55 million in funding. The capital was secured through a Private Investment in Public Equity (PIPE) transaction led by Dr. Patrick Soon-Shiong, founder of NantWorks. According to reports, Dr. Soon-Shiong will also join the PDS Biotech Board of Directors, bringing significant industry expertise to the leadership team.

The company plans to utilize the proceeds to progress the clinical development of PDS0301, an immunocytokine targeting solid tumors. This capital injection is vital for clinical-stage biotech firms maintaining long-term research pipelines. Per market data, PDSB shares closed at $0.22 on September 4, 2026, having traded between a day low of $0.2174 and a high of $0.2378 during that session.

Markets reacted immediately to the news, with PDSB shares surging in premarket trading on September 8, 2026. Traders are now monitoring whether this momentum will carry into the regular session. With the upcoming economic calendar showing no major sector-specific catalysts for the next week, investor attention remains fixed on the company's clinical execution following this high-profile capital injection.